Cost-utility analysis of CAR-T therapy compared to standard of care in patients with relapsed/refractory diffuse large B-cell lymphoma in Colombia, 2025.
- DOI
- 10.1007/s10147-026-03077-0
- Published
- 2026 Sep 2
- Container
- International journal of clinical oncology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s10147-026-03077-0,
title = {Cost-utility analysis of CAR-T therapy compared to standard of care in patients with relapsed/refractory diffuse large B-cell lymphoma in Colombia, 2025.},
author = {Porras Ramírez A and Rico Mendoza A and Encinales L and Madiedo O and Campos Maya MF and Ramón Cuellar JF and Urquijo Méndez JA},
year = {2026},
journal = {International journal of clinical oncology},
doi = {10.1007/s10147-026-03077-0},
url = {https://doi.org/10.1007/s10147-026-03077-0}
}RIS
TY - JOUR TI - Cost-utility analysis of CAR-T therapy compared to standard of care in patients with relapsed/refractory diffuse large B-cell lymphoma in Colombia, 2025. AU - Porras Ramírez A AU - Rico Mendoza A AU - Encinales L AU - Madiedo O AU - Campos Maya MF AU - Ramón Cuellar JF AU - Urquijo Méndez JA PY - 2026 JO - International journal of clinical oncology DO - 10.1007/s10147-026-03077-0 UR - https://doi.org/10.1007/s10147-026-03077-0 ER -
APA
A, P. R., A, R. M., L, E., O, M., MF, C. M., JF, R. C., & JA, U. M. (2026). Cost-utility analysis of CAR-T therapy compared to standard of care in patients with relapsed/refractory diffuse large B-cell lymphoma in Colombia, 2025.. International journal of clinical oncology. https://doi.org/10.1007/s10147-026-03077-0
Source records
- pubmed · retrieved 2026-09-25T19:07:45.068Z